We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Hoth

News List

Hoth Therapeutics and WuXi strike API and drug product deal for cancer therapeutic CPhIonline
November 15, 2021
WuXi will use its new modality platform to provide an end-to-end solution for oligonucleotide peptide.
Hoth Announces Positive Preclinical Results for Novel COVID-19 Therapeutic americanpharmaceuticalreview
March 29, 2021
Hoth Therapeutics announced new in vitro data demonstrating SARS-CoV-2 antiviral activity for its lead peptide candidate for HT-002, a novel therapeutic targeted for the treatment of COVID-19.
Hoth Therapeutics Enters into Commercial Licensing Agreement with University of Maryland, Baltimore and Isoprene Pharmaceuticals Inc. pharmafocusasia
March 14, 2019
Hoth Therapeutics, Inc., a development-stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders...